TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34980609

Group type: EXPERIMENTAL
Intervention: Video group (McGrath Mac videolaryngoscope)
Number of subjects: 256

Group type: COMPARATOR
Intervention: No-video group
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Video group
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 256
Study: 33271319

Group type: EXPERIMENTAL
Intervention: Oral dydrogesterone
Number of subjects: 134

Group type: COMPARATOR
Intervention: Micronized vaginal progesterone (MVP) gel
Number of subjects: 134
Study: 32310162

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE) training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Stretch training (Control)
Number of subjects: 30
Study: 36200919

Group type: EXPERIMENTAL
Intervention: OPF (OpalescencePF‐20%)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: WPC (Whiteness Perfect‐22%)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: PNT (Polanight‐22%)
Number of subjects: 10
Study: 34157027

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 32187781

Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg
Number of subjects: 39
Study: 36055978

Group type: EXPERIMENTAL
Intervention: Low-dose oral ondansetron (0.33 mg twice daily)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 33814891

Group type: EXPERIMENTAL
Intervention: Group Lifestyle Balance Adapted for individuals with Impaired Mobility (GLB‐AIM), a 12‐month intensive lifestyle intervention
Number of subjects: 31
Study: 36036121

Group type: EXPERIMENTAL
Intervention: Prednisone 2 mg/(kg·day) (maximum 60 mg) for 4 weeks
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Prednisone 2 mg/(kg·day) (maximum 60 mg) for 6 weeks
Number of subjects: 89

Group type: COMPARATOR
Intervention: Prednisone treatment for 4 weeks
Number of subjects: 89

Group type: COMPARATOR
Intervention: Prednisone treatment for 6 weeks
Number of subjects: 89
Study: 32050728

Group type: EXPERIMENTAL
Intervention: Inertial measurements using gyroscope and accelerometer from smartphones and wearable IMUs
Number of subjects: 86
Study: 36004653

Group type: EXPERIMENTAL
Intervention: Tirzepatide (5, 10, and 15 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tirzepatide
Number of subjects: 0
Study: 33361493

Group type: EXPERIMENTAL
Intervention: Ankle Kinesio Taping (KT)
Number of subjects: 28
Study: 36193438

Group type: EXPERIMENTAL
Intervention: Low-movement speed training (0.75-0.96 m/s, approximately 60% 1RM)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: High-movement speed training (1.03-1.20 m/s, approximately 40% 1RM)
Number of subjects: 22
Study: 34340194

Group type: EXPERIMENTAL
Intervention: Patient deterioration simulation using inattentional blindness (PDS‐IB)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Simple patient deterioration simulation (control)
Number of subjects: 91
Study: 33124994

Group type: EXPERIMENTAL
Intervention: Web application with personalized avatars for community immunity visualization
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Iterative design process involving multiple users
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Evaluation of users’ emotional responses during design process
Number of subjects: 110

Group type: COMPARATOR
Intervention: Future randomized controlled trial
Number of subjects: 110
Study: 35634869

Group type: EXPERIMENTAL
Intervention: Supervised physical training (tilt training and aerobic exercise)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard care with home tilt training
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Supervised physical training
Number of subjects: 50
Study: 32986116

Group type: EXPERIMENTAL
Intervention: Bypassing healthcare facilities
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Physician referral
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Personal choice
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Recommendation of HMO
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Influence of friends/family/colleagues
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Travel time to farther hospitals
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Travel cost to farther hospitals
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Educational status
Number of subjects: 311
Study: 32291277

Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tirzepatide (10, 15 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dulaglutide 1.5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35462384

Group type: EXPERIMENTAL
Intervention: Concord Centre for Mental Health‐Revised
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Concord Centre for Mental Health‐Original
Number of subjects: 188

Group type: COMPARATOR
Intervention: Generic information package on depression
Number of subjects: 188
Study: 34758761

Group type: EXPERIMENTAL
Intervention: OBEST application combined with standard care
Number of subjects: 77

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 77
Study: 35410292

Group type: EXPERIMENTAL
Intervention: Jockey Club Holistic Support Project for Elderly Mental Wellness (JC JoyAge) model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 0
Study: 35143800

Group type: EXPERIMENTAL
Intervention: Methotrexate 25 mg weekly
Number of subjects: 216

Group type: COMPARATOR
Intervention: Mycophenolate mofetil 1.5 g twice daily
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Methotrexate 25 mg weekly (for those who switched treatment)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Mycophenolate mofetil 1.5 g twice daily (for those who switched treatment)
Number of subjects: 216
Study: 34383954

Group type: EXPERIMENTAL
Intervention: verinurad + allopurinol (12, 7.5 or 3 mg)
Number of subjects: 725

Group type: COMPARATOR
Intervention: allopurinol
Number of subjects: 725

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 725
Study: 35627776

Group type: EXPERIMENTAL
Intervention: Presentation of consensual efficacy findings
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Reported expertise in helmet legislation
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Exposure to results showing a lack of evidence of efficacy
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Participants' helmet use
Number of subjects: 259
Study: 33951086

Group type: EXPERIMENTAL
Intervention: LifeLab educational intervention
Number of subjects: 2929
Study: 32617631

Group type: EXPERIMENTAL
Intervention: Oral opioid rescue medication (hydromorphone) in Cohort 1 (C1)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia (PCIA) with piritramide in Cohort 2 (C2)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Total opioid consumption in Cohort 1 (C1)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Total opioid consumption in Cohort 2 (C2)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Rescue opioids in Cohort 1 (C1)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Basic analgesia opioid use in Cohort 1 (C1)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Functional outcome and patient satisfaction with pain management
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Quality of mobilization, sleep, frequency of nausea and vomiting, general satisfaction with pain management
Number of subjects: 214
Study: 35551086

Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE) followed by further chemotherapy if indicated
Number of subjects: 50

Group type: COMPARATOR
Intervention: Chemotherapy alone (standard of care)
Number of subjects: 50
Study: 34374162

Group type: EXPERIMENTAL
Intervention: Education and counselling about prenatal genetic tests
Number of subjects: 210
Study: 32497956

Group type: EXPERIMENTAL
Intervention: Metacognitions about Smartphone Use Questionnaire (MSUQ) factors
Number of subjects: 701
Study: 36137981

Group type: EXPERIMENTAL
Intervention: TRUShape 25/0.06
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: TRUShape 30/0.06
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Vortex Blue 25/0.06
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Vortex Blue 30/0.06
Number of subjects: 50

Group type: COMPARATOR
Intervention: Positive Control
Number of subjects: 50

Group type: COMPARATOR
Intervention: Negative Control
Number of subjects: 50
Study: 33774192

Group type: EXPERIMENTAL
Intervention: Saline solution with conventional cementation system (etch‐and‐rinse adhesive)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2.5 % sodium hypochlorite (NaOCl) with conventional cementation system (etch‐and‐rinse adhesive)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2.5 % sodium hypochlorite (NaOCl) agitated by passive ultrasonic irrigation (PUI) with conventional cementation system (etch‐and‐rinse adhesive)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Saline solution with conventional cementation system (universal adhesive)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2.5 % sodium hypochlorite (NaOCl) with conventional cementation system (universal adhesive)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2.5 % sodium hypochlorite (NaOCl) agitated by passive ultrasonic irrigation (PUI) with conventional cementation system (universal adhesive)
Number of subjects: 60
Study: 34086911

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass surgery (RYGB)
Number of subjects: 13
Study: 33832816

Group type: EXPERIMENTAL
Intervention: Syndesmosis transfixation with a screw (13 patients)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No fixation (11 patients)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Syndesmosis transfixation with a screw
Number of subjects: 24

Group type: COMPARATOR
Intervention: No fixation
Number of subjects: 24
Study: 32044678

Group type: EXPERIMENTAL
Intervention: Personalized Feedback Intervention (PFI)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Assessment-only controls
Number of subjects: 164
Study: 33579804

Group type: EXPERIMENTAL
Intervention: 68Ga-NODAGA-LM3
Number of subjects: 16

Group type: COMPARATOR
Intervention: 68Ga-DOTA-LM3
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3
Number of subjects: 16
Study: 36169086

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 250 mg once daily for 3 days
Number of subjects: 128

Group type: COMPARATOR
Intervention: Dexamethasone 6 mg once daily for up to 10 days
Number of subjects: 128
Study: 32207776

Group type: EXPERIMENTAL
Intervention: Folic acid and zinc supplementation
Number of subjects: 1503

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1503
Study: 33882590

Group type: EXPERIMENTAL
Intervention: 80 mg of aspirin daily at bedtime
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 35698432

Group type: EXPERIMENTAL
Intervention: Recognition of laterality through implicit motor imagery
Number of subjects: 38

Group type: COMPARATOR
Intervention: Recognition of body parts (Control)
Number of subjects: 38
Study: 34189446

Group type: EXPERIMENTAL
Intervention: Standard of care plus oral IVM at 0.6 mg/kg/day for 5 days
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 45
Study: 34670215

Group type: EXPERIMENTAL
Intervention: FOLFIRI plus cetuximab for all-RAS/quintuple-wildtype disease
Number of subjects: 40

Group type: COMPARATOR
Intervention: FOLFIRI plus bevacizumab in case of RAS mutations
Number of subjects: 40
Study: 32431208

Group type: EXPERIMENTAL
Intervention: Evening exercise group
Number of subjects: 60
Study: 34857397

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 1873

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy (three regimens)
Number of subjects: 1873
Study: 34822113

Group type: EXPERIMENTAL
Intervention: Pitolisant 35.6 mg/day
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study: 33115345

Group type: EXPERIMENTAL
Intervention: Genetic Fuzzy Trees (GFT) system
Number of subjects: 43

Group type: COMPARATOR
Intervention: Comparison to six common classification methods
Number of subjects: 43
Study: 34014315

Group type: EXPERIMENTAL
Intervention: Identified genes conferring salt tolerance from Tamarix hispida
Number of subjects: 1224
Study: 616411777

Group type: EXPERIMENTAL
Intervention: Subconjunctival bevacizumab (1.25 mg/0.1 mL)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Mitomycin C (0.02% for 3 minutes)
Number of subjects: 30
Study: 36216089

Group type: EXPERIMENTAL
Intervention: Eight-week cardiac rehabilitation program
Number of subjects: 80

Group type: COMPARATOR
Intervention: Community-based exercise training
Number of subjects: 80
Study: 33382926

Group type: EXPERIMENTAL
Intervention: Tegoprazan 50 mg administered 30 min before a high-fat meal
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tegoprazan 50 mg administered 30 min after a high-fat meal
Number of subjects: 12

Group type: COMPARATOR
Intervention: Tegoprazan 50 mg in fasting condition
Number of subjects: 12

Group type: COMPARATOR
Intervention: Tegoprazan 50 mg administered in fasting condition
Number of subjects: 12
Study: 35213105

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate, 80 μg plus usual care
Number of subjects: 1201

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1201
Study: 34002944

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) with neoadjuvant chemotherapy
Number of subjects: 52

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy without HCQ (control group)
Number of subjects: 52
Study: 32465510

Group type: EXPERIMENTAL
Intervention: Extracorporeal photopheresis (ECP)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard immunosuppressive therapy (CTR)
Number of subjects: 24
Study: 35505367

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-remifentanil (D-R)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Propofol-remifentanil (P-R)
Number of subjects: 59
Study: 33358843

Group type: EXPERIMENTAL
Intervention: LCPUFA‐120 (40 mg/kg/day DHA and 80 mg/kg/day ARA)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: LCPUFA‐360 (120 mg/kg/day DHA and 240 mg/kg/day ARA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sunflower oil (placebo control)
Number of subjects: 30
Study: 36326825

Group type: EXPERIMENTAL
Intervention: Immediate continuous glucose monitoring (CGM)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Stepped-care group (HypoAware followed by CGM if needed)
Number of subjects: 52
Study: 33176850

Group type: EXPERIMENTAL
Intervention: Surfactant (4 ml, equivalent to 100 mg, administered into the trachea in two doses, starting on the day of intubation with a second dose 6 hours later)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (same volume based on weight, administered into the trachea with the same time schedule)
Number of subjects: 60
Study: 35947315

Group type: EXPERIMENTAL
Intervention: Active low‐level laser (LLL) therapy, 12 sessions
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (equipment without laser)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Active low‐level laser (LLL) therapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (active LLL and placebo)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High-frequency audiometry and acuphenometry outcomes
Number of subjects: 20
Study: 34009725

Group type: EXPERIMENTAL
Intervention: DBLG1 closed-loop system
Number of subjects: 56
Study: 32842812

Group type: EXPERIMENTAL
Intervention: L-arginine/L-citrulline (5 g/day)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269
Study: 33491528

Group type: EXPERIMENTAL
Intervention: Vitamin E 200 IU, Silymarin 750 mg, and l-carnitine 1 gram (VSC) for 18 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33645176

Group type: EXPERIMENTAL
Intervention: Concomitant therapy (CT)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Triple therapy (TRT)
Number of subjects: 211
Study: 33023661

Group type: EXPERIMENTAL
Intervention: CZP 200 mg plus MTX
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: CZP 400 mg plus MTX
Number of subjects: 328

Group type: COMPARATOR
Intervention: MTX plus placebo
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: CZP 200 mg plus MTX and CZP 400 mg plus MTX
Number of subjects: 328
Study: 35402691

Group type: EXPERIMENTAL
Intervention: Intravenous unfractionated heparin (UH) 50 IU/kg bolus during the procedure
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 33714509

Group type: EXPERIMENTAL
Intervention: Pilates training for 12 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 33092617

Group type: EXPERIMENTAL
Intervention: Dentin-pulp biostimulation chitosan membrane (BBio group)
Number of subjects: 468

Group type: COMPARATOR
Intervention: Mineral trioxide aggregate (control group)
Number of subjects: 468
Study: 34247667

Group type: EXPERIMENTAL
Intervention: PEERS intervention
Number of subjects: 82

Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 82
Study: 33947255

Group type: EXPERIMENTAL
Intervention: Triptorelin acetate (0.1 mg) administered on the day of embryo transfer along with routine luteal support
Number of subjects: 893

Group type: COMPARATOR
Intervention: Luteal support only
Number of subjects: 893
Study: 32291596

Group type: EXPERIMENTAL
Intervention: Value for money analyses in non-randomised studies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomised controlled trials
Number of subjects: 0
Study: 35603600

Group type: COMPARATOR
Intervention: Metformin 850 mg twice daily
Number of subjects: 3234

Group type: COMPARATOR
Intervention: Intensive lifestyle intervention
Number of subjects: 3234

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3234

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 3234

Group type: COMPARATOR
Intervention: Lifestyle intervention
Number of subjects: 3234
Study: 35735452

Group type: EXPERIMENTAL
Intervention: True North Peer Navigation (PN) program
Number of subjects: 145
Study: 32415721

Group type: EXPERIMENTAL
Intervention: SBIRT condition (n=354)
Number of subjects: 718

Group type: COMPARATOR
Intervention: Health education condition (n=364)
Number of subjects: 718
Study: 35804452

Group type: COMPARATOR
Intervention: Paclitaxel and carboplatin (2 cycles every 3 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Arsenic trioxide (As2O3) and carboplatin (2 cycles every 3 weeks)
Number of subjects: 60
Study: 33801251

Group type: EXPERIMENTAL
Intervention: Caffeine at a dose of 9 mg/kg body mass
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 32702849

Group type: EXPERIMENTAL
Intervention: Fusu mixture combined with Western medicine
Number of subjects: 620

Group type: COMPARATOR
Intervention: Western medicine treatment group
Number of subjects: 620
Study: 35298060

Group type: EXPERIMENTAL
Intervention: Post-exercise circulatory occlusion (PECO trial)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control trial (rested for four min)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Handgrip exercise
Number of subjects: 32
Study: 32009110

Group type: EXPERIMENTAL
Intervention: Bifal + Arg YG (normal yogurt containing Bifidobacterium animalis ssp. lactis LKM512 and arginine)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Bifal + Arg YG
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (normal yogurt)
Number of subjects: 44
Study: 36333720

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 33612376

Group type: EXPERIMENTAL
Intervention: Prostatic artery embolisation (PAE)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 103
Study: 32353619

Group type: EXPERIMENTAL
Intervention: Suture Tape (ST)
Number of subjects: 28

Group type: COMPARATOR
Intervention: High-Strength Suture (HSS)
Number of subjects: 28
Study: 33403738

Group type: EXPERIMENTAL
Intervention: Low-concentration carbohydrate solution (300 mL) taken 2 hours before induction of anesthesia
Number of subjects: 85

Group type: COMPARATOR
Intervention: Warm water (control)
Number of subjects: 85
Study: 32585900

Group type: EXPERIMENTAL
Intervention: Stilbenes
Number of subjects: 1874

Group type: EXPERIMENTAL
Intervention: Flavonoids
Number of subjects: 1874
Study: 34448710

Group type: EXPERIMENTAL
Intervention: Web-based self-help program (Alcohol e-Health)
Number of subjects: 1400
Study: 32186016

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS) at Zusanli (ST 36) before and during surgery
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no stimulation)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS) at Zusanli (ST 36)
Number of subjects: 64
Study: 35120284

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH; 20 mg/d)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 33587678

Group type: EXPERIMENTAL
Intervention: Following the evolution of the COVID-19 pandemic in Lebanon
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Higher compulsion
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Having a university level of education
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Following the evolution of the COVID-19 pandemic in Lebanon (all of the time, most of the time, sometimes, little of the time)
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Higher age
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Being male
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Higher depression
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Practicing religion some of the time
Number of subjects: 386
Study: 35470194

Group type: EXPERIMENTAL
Intervention: Labour induction at 39 weeks and 0 to 3 days of gestation
Number of subjects: 1900

Group type: COMPARATOR
Intervention: Expectant management (waiting for spontaneous labour onset or induction if medically indicated)
Number of subjects: 1900
Study: 34022051

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg daily
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 34098291

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 94